FDA Gives Nod to Melanoma Drug

The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.

By Jef Akst | September 8, 2014

3-D structure of a melanoma cell WIKIMEDIA, SRIRAM SUBRAMANIAM, NCIWith the US Food and Drug Administration’s final green light last week (September 4), Merck’s pembrolizumab, which the pharmaceutical giant plans to market as Keytruda, is the first US-approved drug that blocks the immune brake known as programmed death receptor 1 (PD-1), unleashing certain immune cells to wreak havoc on a patient’s tumor. The approval—which “followed a swift review of data from a relatively early-stage human trial,” The Wall Street Journal (WSJ) reported—will allow doctors to prescribed the drug in cases of melanoma, though some researchers emphasize the promise of pembrolizumab and similar drugs for other types of cancer, as well.

“PD-1 is truly a game-changer. It’s active in a way that other drugs are not,” Lynn Schuchter, a medical oncologist who heads the melanoma program at the Abramson Cancer Center of the University of Pennsylvania and has assisted in clinical trials of the Merck drug, told WSJ. “And what’s been interesting is the activity of PD-1 beyond melanoma. It looks to be active in bladder and renal and lung cancer. So this is bigger than melanoma.”

In a clinical trial this summer, more than two-thirds of advanced melanoma patients who received pembrolizumab survived at least one year post-treatment; 62 percent were alive after 18 months, the researchers reported. The trial also revealed notable tumor shrinkage in about one-third of patients. Merck now must run two additional trials “to verify that the drug can prolong lives and delay the progression of disease,” The New York Times (NYT) reported.

While pembrolizumab is the first PD-1 inhibitor approved for use in the U.S., another drug of this class, Bristol-Myers Squibb (BMS) and Ono Pharmaceutical’s nivolumab was recently approved in Japan. Both drugs come with a hefty price tag: $150,000 per year, for Merck’s pembrolizumab; $143,000 a year for BMS and Ono’s nivolumab, which is likely to soon be reviewed US regulators, according to WSJ. Roche and AstraZeneca also have PD-1 inhibitors in development. (For more on other types of immunotherapies, see “Deploying the Body’s Army,” The Scientist, April 2014.)

“This [approval] is really opening up a whole new avenue of effective therapies previously not available,” Louis Weiner, director of the Georgetown Lombardi Comprehensive Cancer Center in Washington and a spokesman for the American Association for Cancer Research, told NYT. “It allows us to see a time when we can treat many dreaded cancers without resorting to cytotoxic chemotherapy.”

Update (September 8): Shortly after posting this story, The Scientist learned that Bristol-Myers Squibb and Ono Pharmaceuticals, which recently saw their PD-1 inhibitor approved in Japan, are suing Merck for violating the BMS/Ono patent "for a method of harnessing the body's immune system to fight cancer," WSJ reported.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo


Avatar of: Dr. Jonas Moses

Dr. Jonas Moses

Posts: 22

September 8, 2014

I shall eagerly await other clinical studies desmonstrating the efficacy of treating these cancers by enlisting the body's immune system, rather than resorting to harmful chemotherapy and radiation. I (and others) have been promoting redirecting our therapeutic efforts to the human immune response for many years.

Perhaps, with this news, we can find cause for optimism -- that such deadly treatments as radiation and chemotherapy may finally (and rightfully) become mere footnotes in the history of Human Medicine.

Respectfully, Dr. Jonas Moses

Avatar of: DeepBlueSci


Posts: 5

September 8, 2014

This is why basic medical research should be supported. It was fundamental scientific research in genetically modified mice that identified the key role of PD-1 in regulating the immune system. Investing in science pays off! http://speakingofresearch.com/2013/12/20/cancer-immunotherapy-a-breakthrough-made-through-animal-research/

Popular Now

  1. Two University of Rochester Professors Resign in Protest
  2. Dartmouth Professor Investigated for Sexual Misconduct Retires
  3. Theranos Leaders Indicted For Fraud
    The Nutshell Theranos Leaders Indicted For Fraud

    Federal prosecutors filed criminal charges that allege the company’s promise to revolutionize blood testing swindled investors out of hundreds of millions of dollars and put patients in danger.

  4. Koko the Signing Gorilla Dies at 46